mRNA redesigned medicine redefined

 

TECHNOLOGY

01

Robust

02

Cell Specific

Kernal's synthetic biology-based approach includes the development of a platform using deep learning algorithms and big data to create better designed mRNAs.

Smart engineering makes our mRNAs specific for certain cell or tissue types., 

03

Stealth 

Our proprietary design and manufacturing processes enable the evasion of RNA sensors, particularly for repetitive applications. 

MEET KERNAL

 

SUPPORTERS & MEMBERSHIPS

Memberships
kernal biologics

Boston 2018 Winner

2019 Spring Cycle

Supporters
 
 

NEWS FROM US

Kernal to target COVID-19 pandemic

The company is leveraging its proprietary mRNA technology against COVID-19

Kernal Biologics is developing mRNA therapeutics to target SARS-CoV-2 with the nation's leading infectious disease groups and high containment research facilities. It is also opening its stealth mRNA platform to researchers and companies working on vaccines and therapeutics for COVID-19. 

Kernal team has access to industry experts and veterans for mentorship and advice

MassBio® Welcomes Four Life Sciences Startups to Participate in MassCONNECT® Spring Mentorship Cycle. Kernal is among the companies that was selected for the 2019 Spring program.
 

Kernal's disruptive mRNA 2.0 technology gets more recognition

Kernal gets a second award from Amgen, the Biotech giant that pioneered BiTE® immunotherapy and T-VEC (Imlygic™), the first oncolytic virus therapy approved by the FDA. 

1 / 3

Please reload

STAY IN TOUCH

 
LINKS
ABOUT

kernal@kernalbio.com

Tel: 857-600-0762

700 Main Street, North
Cambridge, MA 02139 

SOCIAL
  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon
  • White Google+ Icon

© 2018 by Kernal Biologics, Inc.